Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.00M | $160M | $305M | $438M | $582M | $715M | $868M |
| Revenue growth | — | 2564.6% | 91.2% | 43.4% | 32.9% | 22.8% | 21.5% |
| Gross profit | $4.42M | $132M | $250M | $354M | $461M | $558M | $670M |
| Gross margin | 73.7% | 82.6% | 81.8% | 80.9% | 79.2% | 78.1% | 77.2% |
| Operating income | -$146M | $17.0M | $87.5M | $120M | $192M | $191M | $208M |
| Operating margin | -2433.8% | 10.6% | 28.7% | 27.4% | 33.0% | 26.7% | 24.0% |
| Net income | -$152M | -$36.9M | $34.6M | $181M | $129M | $145M | $159M |
| Net margin | -2535.1% | -23.1% | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% |
| EPS (diluted) | -$24.07 | -$2.48 | $0.58 | $2.97 | $2.13 | $2.51 | $2.71 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75.4M | -$2.98M | $98.6M | $144M | $219M | $220M | $348M |
| Capital expenditures | $149K | $2.00K | $298K | $172K | $312K | $1.15M | $310K |
| Free cash flow | -$75.6M | -$2.99M | $98.3M | $144M | $219M | $219M | $348M |
| Share buybacks | — | $167K | — | — | $100M | — | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.5M | $229M | $234M | $244M | $312M | $453M | $753M |
| Total assets | $107M | $427M | $433M | $674M | $811M | $999M | $1.27B |
| Total liabilities | $118M | $330M | $247M | $271M | $344M | $340M | $401M |
| Long-term debt | $97.9M | $194M | $190M | $190M | $179M | $163M | $144M |
| Shareholders' equity | -$423M | $97.2M | $187M | $403M | $467M | $659M | $870M |
| Retained earnings | -$423M | -$488M | -$454M | -$272M | -$143M | $2.22M | $161M |
| Shares (wtd avg diluted) | 7.78M | 25.8M | 59.2M | 61.1M | 60.4M | 57.9M | 58.5M |
Every figure is extracted from Harmony Biosciences Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.